Grass City 20% OFF

CFN Media Group (“CannabisFN”), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article covering India Globalization Capital Inc.(NYSE:IGC) and its shift into the cannabis industry. India Globalization operates a legacy infrastructure business that consists of heavy equipment rental, real estate management, and commodities trading, but its primary focus has shifted to medical cannabis in recent years and more recently to blockchain. Investors interested in the space may want to take a closer look given its near-term clinical trials and long-term focus on developing blockchain technologies to solve critical issues facing the industry.

SeeThruEquity, a leading independent equity research firm focused on emerging public companies, issued an update note on January 8, 2018 and raised its price target on the stock to $2.00. This represents a significant 100%+ premium to the current market price of $0.97 per share.

<b>Near-term Cannabinoid Pipeline</b>

India Globalization Capital is a leading cannabis-based pharmaceutical company with a pipeline of products designed to improve the lives of patients battling Alzheimer’s disease, Parkinson’s disease, chronic pain, post-traumatic stress disorder, and eating disorders. Under the guidance of its Science Officer Dr. Jagadeesh Rao, Ph.D., the company is working on four different proprietary cannabinoid-based products targeting serious medical conditions.

— Hyalolex – A proprietary cannabinoid formulation that includes low doses of THC and is intended to disrupt the buildup of amyloid beta plaque and alleviate some of the worst symptoms of Alzheimer’s disease.

— Serosapse – A cannabinoid formulation targeting certain end points of Parkinson’s disease.

— Caesafin – A phytocannabinoid therapy designed to alleviate seizures in cats and dogs.

— Natrinol – A cannabinoid formulation designed for AIDS and cancer induced nausea and vomiting, as well as for appetite stimulation.

These four products are divided into seven different clinical programs with some pre-clinical and clinical trials expected to begin later this year:

IGC-501 — Neuropathic Pain — Adults — N/A

IGC-502 — Seizures — Veterinary — 2019

IGC-503 — Refractory Epilepsy — Adults — N/A

IGC-504 — Eating Disorders — Adults & Veterinary — 2018

IGC-505 — Seizures — Veterinary — N/A

IGC-506 — Eating Disorders — Adults & Veterinary — N/A

IGC-ADI — Alzheimer’s Disease — Adults — 2018

The most critical and near-term clinical trials would be for Hyalolex for the treatment of patients with Alzheimer’s disease. This therapy is based on research conducted by Dr. Chuanhai Cao, Associate Professor of Pharmacy at the University of South Florida, who has already demonstrated signs of efficacy in both in vivo and in vitro studies. Alzheimer’s disease is the most expensive disease to treat at nearly $260 billion per year, according to the Alzheimer’s Association, surpassing both heart disease and cancer. These costs are expected to balloon to $758 billion by 2050, which creates an enormous need for effective treatment options.

In addition to FDA clinical trials, the company expects to license its formulation technology for distribution as a Complementary and Alternative Medicine (CAM) through licensed medical cannabis dispensaries in key medical markets in the United States and Canada. Management expects to bring the medication to patients in select markets in early 2018, with subsequent expansion to additional U.S. states dependent on product procurement and associated compliance achievement. These activities could generate nearer-term revenue as clinical trials progress, which creates both short- and long-term value for shareholders.

<b>Expanding into Blockchain Tech</b>

India Globalization Capital recently announced that it would leverage its existing team of technology and health care experts to develop methods utilizing blockchain technology in areas such as product identification assurance. In particular, the team hopes to address a recent study that was published showing that nearly 70 percent of all cannabidiol (CBD) products sold online are either over or under labeled, which can be dangerous for consumers. Blockchain technology involves the creation of a verifiable digital ledger to avoid these problems.

“We understand the unique challenges facing the cannabis industry and believe that our team has the expertise to be the first to create meaningful solutions to address these issues using distributed ledgers inherent in blockchain technology,” said CEO Ram Mukunda. “As we work to develop blockchain in the rollout of Hyalolex, our goal would be to establish a universal cannabis platform applicable to solving multiple industry challenges.”

Initially, the company hopes to apply the blockchain technology to its rollout of Hyalolex. The move could create a valuable proof of concept prior to a rollout of the platform as an independent product that could be licensed within the industry. The goal would be to address issues like transactional difficulties, inadequate product labeling, product identification assurance, and product origin assurance for patients, regulators, and dispensaries.

<b>Please follow the link to read the full article:</b>

For more information about the company visit the company’s website at

For more information on its cannabis pharmaceutical products visit:

For more information on Hyalolex visit:

<b>About CFN Media</b>

CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

Learn how to become a CFN Media client company, brand or entrepreneur:

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand:

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone:

<b>Disclaimer</b> is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate., a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. received compensation for producing and presenting high quality and sophisticated content on along with financial and corporate news.

The above article is sponsored content. Emerging Growth LLC, which owns and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation:

CFN MediaFrank

<img src=”” alt=”” width=”1″ height=”1″/>

Stock Symbols